A5015707923- Colorectal Cancer Treatments and Studies
- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Colorectal and Anal Carcinomas
- Gastric Cancer Management and Outcomes
- Neuroblastoma Research and Treatments
- Colorectal Cancer Surgical Treatments
- Pancreatic and Hepatic Oncology Research
- Cancer Treatment and Pharmacology
- Hepatocellular Carcinoma Treatment and Prognosis
- Genetic factors in colorectal cancer
- Cancer Research and Treatments
- Cancer Genomics and Diagnostics
- Cancer, Hypoxia, and Metabolism
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Gastrointestinal Tumor Research and Treatment
- Virus-based gene therapy research
- Economic and Financial Impacts of Cancer
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Nutrition and Health in Aging
- Chronic Lymphocytic Leukemia Research
- Bladder and Urothelial Cancer Treatments
- Cancer and Skin Lesions
Hospital Universitario 12 De Octubre
2015-2024
Moffitt Cancer Center
2021-2024
Research Institute Hospital 12 de Octubre
2014-2024
Spanish National Cancer Research Centre
2023
Centro de Investigación Biomédica en Red
2022
Centro de Investigación Biomédica en Red de Cáncer
2017-2021
Centro Nacional de Epidemiología
2020
Hospital Universitario Ramón y Cajal
2019
Universidad Complutense de Madrid
2017
University of Toronto
2014-2016
Background Pancreatic ductal adenocarcinoma (PDAC) is characterized by dense desmoplastic stroma that limits the delivery of anticancer agents. VCN-01 an oncolytic adenovirus designed to replicate in cancer cells with a dysfunctional RB1 pathway and express hyaluronidase. Here, we evaluated mechanism action preclinical models patients pancreatic cancer. Methods replication antitumor efficacy were alone combination standard chemotherapy immunodeficient immunocompetent using intravenous or...
VCN-01 is an oncolytic adenovirus (Ad5 based) designed to replicate in cancer cells with dysfunctional RB1 pathway, express hyaluronidase enhance virus intratumoral spread and facilitate chemotherapy immune extravasation into the tumor. This phase I clinical trial was aimed find maximum tolerated dose/recommended II dose (RP2D) dose-limiting toxicity (DLT) of intravenous delivery replication-competent patients advanced cancer.Part I: refractory solid tumors received one single VCN-01. Parts...
Abstract Background Peptide receptor radionuclide therapy (PRRT) is one of the most promising therapeutic strategies in neuroendocrine neoplasms (NENs). Nevertheless, its role certain tumor sites remains unclear. This study sought to elucidate efficacy and safety [ 177 Lu]Lu-DOTATATE NENs with different locations evaluate effect origin, bearing mind other prognostic variables. Advanced overexpressing somatostatin receptors (SSTRs) on functional imaging, any grade or location, treated at 24...
Cachexia is a metabolic syndrome that affects up to 50-80% of cancer patients. The pathophysiology characterized by variable combination reduced food intake and abnormal metabolism, including systemic inflammation negative protein energy balance. Despite its high clinical significance, defined diagnostic criteria established therapeutic strategies are lacking. 'omics' technologies provide global view biological systems. We hypothesize blood-based metabolomics might identify findings in...
BackgroundSolid tumour growth is the consequence of a complex interplay between cancer cells and their microenvironment. Recently, new global transcriptomic immune classification solid tumours has identified six subtypes (ISs) (C1–C6). Our aim was to specifically characterise ISs in colorectal (CRC) assess with consensus molecular (CMSs).MethodsClinical information, including CMSs ISs, were obtained from The Cancer Genome Atlas (TCGA) (N = 625). Immune cell populations, differential gene...
PURPOSE Somatostatin analogs (SSAs) are recommended for the first-line treatment of most patients with well-differentiated, gastroenteropancreatic (GEP) neuroendocrine tumors; however, benefit from is heterogeneous. The aim current study was to develop and validate a progression-free survival (PFS) prediction model in SSA-treated patients. PATIENTS AND METHODS We extracted data Spanish Group Neuroendocrine Endocrine Tumors Registry (R-GETNE). Patient eligibility criteria included GEP...
The prognosis of patients with advanced high-grade (G3) digestive neuroendocrine neoplasms (NENs) is rather poor. addition immune checkpoint inhibition to platinum-based chemotherapy may improve survival. NICE-NEC (NCT03980925) a single-arm, phase II trial that recruited chemotherapy-naive, unresectable or metastatic G3 NENs gastroenteropancreatic (GEP) unknown origin. Patients received nivolumab 360 mg intravenously (iv) on day 1, carboplatin AUC 5 iv and etoposide 100 mg/m
40 Background: TNT has recently emerged as a standard treatment for LARC. However, use and outcome of the different regimens in real-world practice are largely unknown. Methods: This is an international, multicentre, retrospective study sponsored by Institut Jules Bordet, Brussels. Eligibility was limited to newly diagnosed LARC patients treated with between March 2013 May 2023 outside context clinical trial. The primary objective describe real-word across international centres. Secondary...
Abstract Purpose Panitumumab plus FOLFOX (P-FOLFOX) is standard first-line treatment for RAS wild-type (WT) metastatic colorectal cancer. The value of panitumumab rechallenge currently unknown. We assessed addition to FOLFIRI (P-FOLFIRI) beyond progression P-FOLFOX in patients with no mutations liquid biopsy (LB). Methods In this randomized phase II trial, were assigned (3:2 ratio) second-line P-FOLFIRI (arm A) or alone B). LB circulating tumor DNA analysis was collected at study entry and...
Previously, we reported the modest but durable anticancer activity of regorafenib/nivolumab in mismatch repair-proficient (pMMR) refractory colorectal cancer our I/Ib study. Our finding suggests necessity biomarkers for better selection patients. Baseline clinical and pathological characteristics, blood tumor samples from patients trial were collected evaluated to discover potential biomarkers. The obtained assessed immunohistochemistry, ELISA RNA sequencing. Their correlations with outcome...
Purpose: Patients with unresectable wild-type KRAS metastatic colorectal cancer benefit from fluoropyrimidines (FP), oxaliplatin (O), irinotecan (I), bevacizumab (Bev), and epithelial growth factor receptor inhibitors (EGFRI). The most cost-effective regimen remains unclear. Methods: A Markov model was constructed to examine the costs outcomes of three treatment strategies: strategy (reference strategy): EGFRI monotherapy in third line ([3L]; ie, first-line [1L]: Bev + FOLFIRI [FP I] or...
Combination of capecitabine and irinotecan (XELIRI regimen) is an active well tolerated treatment for metastatic colorectal cancer (mCRC). The aim this study was to evaluate the efficacy safety regimen in combination with bevacizumab (BV), as first-line mCRC. A total 46 consecutive patients received a BV (5 mg kg−1, day 1), (175 m−2, 1) (1000 m−2 twice daily on 2–8), every 2 weeks. Patients were treated until disease progression or unacceptable toxicity. primary objective determine...
Purpose: High-throughput “-omic” technologies have enabled the detailed analysis of metabolic networks in several cancers, but NETs not been explored to date. We aim assess metabolomic profile NET patients understand deregulation these tumors and identify novel biomarkers with clinical potential. Methods: Plasma samples from 77 68 controls were profiled by GC−MS, CE−MS LC−MS untargeted metabolomics. OPLS-DA was performed evaluate differences. Related pathways using Metaboanalyst 4.0....